Martin Glensbjerg takes up new position at ChemoMetec

2 years ago

ANNOUNCEMENT NO. 248 20 December 2023 Martin Glensbjerg takes up a new role in ChemoMetec COO and deputy chairman of…

Kriya to Present at the J.P. Morgan 42nd Annual Healthcare Conference

2 years ago

PALO ALTO, Calif., and RESEARCH TRIANGLE PARK, N.C., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc. ("Kriya"), a biopharmaceutical…

Shockwave Medical to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

2 years ago

SANTA CLARA, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and…

Significant Health and Quality of Life Improvements Achieved in Children with Achondroplasia Treated for One Year with TransCon™ CNP (Navepegritide) at 100 µg/kg/week

2 years ago

TransCon CNP is the first investigational product to demonstrate improvements in health-related quality of life and disease impacts in children…

Kane Biotech Receives Offer for its Interest in STEM Animal Health

2 years ago

Proposed transaction allows for sharpened focus on Human HealthWINNIPEG, Manitoba, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE…

Akoya to Participate at 42nd Annual J.P. Morgan Healthcare Conference

2 years ago

MARLBOROUGH, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced…

Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study

2 years ago

Data Support Continued Clinical Development of DARE-PDM1 and its Potential as a First-in-Category Treatment for Primary DysmenorrheaSAN DIEGO, Dec. 20,…

Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial of Lomecel-B™ in the Treatment of Mild Alzheimer’s Disease

2 years ago

New clinical data showed that Lomecel-B™ improved cognitive function in multiple measures in a dose-response fashion Caregiver ratings documented improved quality…

Awakn Life Sciences Enters Global Licensing Agreement For Proprietary Sublingual S-Ketamine Formulation With LTS

2 years ago

Agreement Includes Exclusive Rights for Treatment of Addiction, Anxiety and Eating DisordersAlso Includes Access to Phase 1 Data and Patents…

Boomerang Medical’s IBD Neuromodulation Study Successfully Completes Enrollment Milestone

2 years ago

Pioneering Bioelectronic Research Advances in the Fight Against Inflammatory Bowel DiseaseMOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Boomerang Medical, Inc., a women-led bioelectronic medicine…